Hangzhou Tigermed
Hangzhou Tigermed Consulting Co., Ltd., commonly known as Tigermed, is a leading clinical research organisation headquartered in Hangzhou, China. Founded in 2004, the company has established a strong presence across Asia, Europe, and North America, providing comprehensive services in the pharmaceutical and biotechnology sectors. Tigermed specialises in clinical trial management, regulatory affairs, and data management, offering unique solutions that streamline the drug development process. With a commitment to quality and innovation, the company has achieved significant milestones, including numerous successful trials for global clients. Recognised for its expertise and reliability, Tigermed holds a prominent position in the industry, contributing to advancements in healthcare and supporting the development of new therapies. Its dedication to excellence has earned it a reputation as a trusted partner in clinical research.
DitchCarbon Score
How does Hangzhou Tigermed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hangzhou Tigermed's score of 27 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hangzhou Tigermed's reported carbon emissions
In 2023, Hangzhou Tigermed Consulting Co., Ltd. reported total carbon emissions of approximately 2,136,860 kg CO2e, with Scope 1 emissions at about 94,270 kg CO2e and Scope 2 emissions at approximately 2,042,580 kg CO2e. This marked an increase from 2022, where total emissions were around 2,163,020 kg CO2e. The company has shown a significant rise in emissions over the years, with total emissions in 2021 recorded at about 1,438,920 kg CO2e. Tigermed has committed to near-term emissions reduction targets, although specific numerical targets have not been disclosed. The company is not currently committed to a net-zero target. Their emissions data indicates a focus on Scope 1 and Scope 2 emissions, with no reported Scope 3 emissions data. As a player in the Pharmaceuticals, Biotechnology, and Life Sciences sector, Tigermed's climate commitments reflect an awareness of the industry's impact on climate change, and they are actively working towards improving their sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 63,180,000 | 00,000,000 | 00,000 | 00,000 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 1,037,878,000 | 0,000,000,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hangzhou Tigermed is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
